OUR PORTFOLIO OF COMPANIES
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Drug candidates are based upon Leukothera, a natural protein that targets and eliminates white blood cells involved in the mechanism of many diseases.
Affineti Biologics, Inc. is advancing its research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine.
Kayothera is developing new therapeutics to give hope to one of the most vulnerable patient populations - people with late stage or metastatic cancers. With these novel therapies, the aim is to cure incurable cancers and give hope back to patients.
NemaGen Discoveries is an early phase biotech company that is focused on advancing therapies to prevent allergic inflammation and mast-cell related diseases.
NovoPedics is developing an implantable medical that restores mobility to patients suffering from severe mensical knee injuries. The company's first product, Meniscofix, is a biodegradable polymer, fiber reinforced scaffold for total meniscal replacement.
OculoMotor Technologies combines virtual reality based vision therapy with on board eye tracking to provide therapeutic effect to patients suffering from convergence insufficiency.
MentiNova's primary strategy is to use a drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson's disease. This path can provide a critically needed medication in a rapid timeframe.
Foundation Venture Capital Group sold its equity interest in Durin to Breakthrough Diagnostics, LLC. Durin continues to pursue the development of blood tests to detect neurodegenerative diseases at very early stages.
Foundation Venture Capital Group sold its equity interest in Visikol, Inc. to CELLINK. Visikol continues to focus on advanced imaging, 3D cell culture assays and digital pathology.
Foundation Venture Capital Group sold its equity interest in Longevica to Rostock International, Ltd., a subsidiary of Rostock Group, a Moscow (Russia) headquartered global investment firm focused on investments in breakthrough technologies that can radically increase human lifespan and improve quality of life.
Good Science Makes Good Business™